ISA-2011B is primarily utilized in the field of biomedical research, particularly in the study of cancer therapeutics. It functions as a potent inhibitor of specific signaling pathways that are often dysregulated in various cancers. Researchers use this compound to investigate its efficacy in halting tumor growth and inducing apoptosis in cancer cells. Its application extends to preclinical studies where it is tested in cell cultures and animal models to evaluate its potential as a targeted therapy. Additionally, ISA-2011B is explored for its ability to enhance the effectiveness of existing chemotherapy drugs, potentially reducing the required dosage and minimizing side effects. Its role in advancing personalized medicine is significant, as it helps in understanding the molecular mechanisms underlying cancer progression and resistance to treatment.